论文部分内容阅读
以表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitor,EGFR-TKI)分子靶向治疗研究为肇始,转化性研究使基础实验和临床实践间的鸿沟迅速填平,改变着人们认识治疗肺癌的视角。无可否认,EGFR-TKI上市后极大地延伸了肿瘤学家治疗肺癌的手段,但不管从临床经验、临床研究数据、分子生物学层面还是文献计量学的角度,都会发现制约EGFR-TKI进一步应用的两个瓶颈分别是:EGFR-TKI临床、
The study of molecular targeted therapy with the epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) was initiated, and transformational research quickly filled the gap between basic experiments and clinical practice. Change people’s understanding of the perspective of treating lung cancer. Undoubtedly, the onset of EGFR-TKI has greatly extended the oncologists’ treatment of lung cancer. However, from the perspective of clinical experience, clinical research data, molecular biology, and bibliometrics, it will be found that restricting EGFR-TKI for further applications The two bottlenecks are: EGFR-TKI clinical,